Genygi Life Sciences
Private Limited

Oncology

Sorafgen-200

Packed:	120 Tablets
Manufacturer:	Hetero Labs Limited
Active ingredient:	Sorafenib

Sorafenib Sorafgen-200 is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and thyroid cancer.

Download Documentation

Reviews (0)

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Sorafgen-200”

Disclaimer:

This medical information is intended exclusively for healthcare professionals in India. The products discussed herein may have different labeling and regulatory requirements in other countries.

The information provided on this site is scientific, evidence-based, and intended to address unsolicited medical inquiries in a balanced manner.

For full Prescribing Information, including indications, contraindications, warnings, precautions, and potential adverse events, please submit a medical information request.

This content is not intended as medical advice. Responsibility for patient care rests solely with the healthcare professional, based on their professional license, expertise, and knowledge of the patient.

This website does not engage in the sale or purchase of any medicines.

Sorafgen-200

Reviews

Abiragen-250

Enzalutagen-40

Imatigen-100

Imatigen-400

Sunitigen-25

Sunitigen-50

Tamoxigen-20

Genygi Life Sciences Private Limited

Sorafgen-200

Reviews

Related products

Abiragen-250

Enzalutagen-40

Imatigen-100

Imatigen-400

Sunitigen-25

Sunitigen-50

Tamoxigen-20

Genygi Life Sciences Private Limited